Identifying Inflammatory Markers Related to Toxicities Early Can Improve Multiple Myeloma Treatment

Understanding the immune landscape of CAR T-related toxicities and responses can improve outcomes

Are Cellular Therapies the New Frontier in Cancer Treatment?

Moffitt experts discuss the latest in cellular therapy at annual Research Innovation event

Patient Marks Moffitt’s 1,000th CAR T Treatment

The immunotherapy has only been available to multiple myeloma patients for a little over a year

Moffitt Researchers Target Cellular Process to Improve Multiple Myeloma Outcomes

Inhibiting autophagy key to beating chemo resistance

Cell Therapy Superior to Standard of Care for Multiple Myeloma

Phase 3 trial results show improved response rate and reduced risk of disease progression

Hematologist Trains at Moffitt, Hoping to Benefit Armenians

Through a visiting physician program, a doctor is learning the intricacies of an allogeneic BMT procedure and care to help his home country

Save A Life This Month by Donating Blood

January is National Blood Donor Awareness Month

Endeavor